China National Accord Medicines Corporation Ltd.
First Quarterly Report 2018
April 2018
1
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord
Medicines Corporation Ltd. (hereinafter referred to as the Company) and its
directors, supervisors and senior executives should guarantee the reality,
accuracy and completion of the quarterly report, there are no any fictitious
statements, misleading statements or important omissions carried in this report,
and shall take legal responsibilities, individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Lin Zhaoxiong person in charge of the Company, Wei Pingxiao, person in
charge of accounting works and Wang Ying, person in charge of accounting
organ (accounting officer) hereby confirm that the Financial Report of this
Quarterly Report is authentic, accurate and complete.
2
Section II. Company profile
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data
□ Yes √No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 10,256,566,731.51 10,222,459,812.55 0.33%
Net profit attributable to shareholders of
292,731,685.33 272,564,318.71 7.40%
the listed company (RMB)
Net profit attributable to shareholders of
the listed company after deducting 284,982,162.39 271,249,398.43 5.06%
non-recurring gains and losses (RMB)
Net cash flow arising from operating
-864,716,289.96 -502,263,276.11 -72.16%
activities (RMB)
Basic earnings per share (RMB/Share) 0.68 0.64 6.25%
Diluted earnings per share (RMB/Share) 0.68 0.64 6.25%
Weighted average ROE 3.07% 3.17% -0.10%
Changes of this period-end
At the end of the reporting
At the end of last year over same period-end of last
period
year
Total assets (RMB) 23,760,905,981.51 22,343,643,527.77 6.34%
Net assets attributable to shareholder of
9,689,304,031.21 9,396,572,345.88 3.12%
listed company (RMB)
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Amount from year-begin to
Item Note
period-end
Revenue from intangible assets
Gains/losses from the disposal of non-current asset (including the disposal by subsidiary –
3,830,300.39
write-off that accrued for impairment of assets) Sinopharm Holding Guangxi
Logistic Co., Ltd.
Governmental subsidy reckoned into current gains/losses (not
Mainly due to the various special
including the subsidy enjoyed in quota or ration according to
2,094,366.02 grants received in the current
national standards, which are closely relevant to enterprise’s
period.
business)
3
The bad debt of receivables
Reversal of impairment reserve for account receivable with
3,740,941.40 accrual independently previous
separate impairment testing
year has collected in the period
Other non-operating income and expenditure except for the
60,814.75
aforementioned items
Less: impact on income tax 1,942,073.91
Impact on minority shareholders’ equity (post-tax) 34,825.71
Total 7,749,522.94 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
Total preference shareholders
Total common shareholders
with voting rights recovered at
17,838 0
at the end of report period end of reporting period (if
applicable)
Top ten shareholders
Amount of
Shareholder’s Nature of Proportion of Amount of shares Number of share pledged/frozen
restricted shares
name shareholder shares held held State of share Amount
held
Sinopharm Group State-owned legal
56.06% 239,999,991 55,057,700
Co., Ltd. person
HTHK/CMG
FSGUFP-CMG
Foreign
FIRST STATE 2.37% 10,141,182 0
Corporation
CHINA
GROWTH FD
China Life
Domestic non
Insurance Co.,
state-owned legal 2.05% 8,777,292 0
Ltd. – tradition –
person
general insurance
4
products -
005L-CT001
Shen
China United
Property
Insurance Domestic non
Company
state-owned legal 1.42% 6,092,905 0
Limited -
Traditional person
insurance
products
China National
Pharmaceutical State-owned legal
1.24% 5,323,043 5,323,043
Foreign Trade person
Corporation
GUOTAI
JUNAN
Foreign
SECURITIES(H 1.23% 5,268,100 0
Corporation
ONGKONG)
LIMITED
TARGET Foreign
1.01% 4,321,860 0
VALUE FUND Corporation
New China Life
Insurance Co.,
Domestic non
Ltd. – Bonus –
Individual state-owned legal 0.99% 4,229,772 0
bonuses -
person
-018L-FH002
Shen
# Beijing
Haoqing Fortune
Investment Domestic non
Management Co., state-owned legal 0.95% 4,048,216 0
Ltd. – Haoqing person
Value Stable No.8
Investment Fund
Central Huijin State-owned legal
0.89% 3,804,400 0
Investment Ltd. person
Top ten shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Holding Co., Ltd. 184,942,291 184,942,291
shares
HTHK/CMG FSGUFP-CMG FIRST Domestic listed
10,141,182 10,141,182
STATE CHINA GROWTH FD foreign shares
China Life Insurance Co., Ltd. – 8,777,292
RMB ordinary
8,777,292
tradition –general insurance products shares
5
-005L-CT001 Shen
China United Property Insurance
RMB ordinary
Company Limited - Traditional 6,092,905 6,092,905
shares
insurance products
GUOTAI JUNAN
Domestic listed
SECURITIES(HONGKONG) 5,268,100 5,268,100
foreign shares
LIMITED
Domestic listed
TARGET VALUE FUND 4,321,860 4,321,860
foreign shares
New China Life Insurance Co., Ltd.
RMB ordinary
– Bonus – Individual bonuses - 4,229,772 4,229,772
shares
-018L-FH002 Shen
# Beijing Haoqing Fortune
Investment Management Co., Ltd. – RMB ordinary
4,048,216 4,048,216
Haoqing Value Stable No.8 shares
Investment Fund
RMB ordinary
Central Huijin Investment Ltd. 3,804,400 3,804,400
shares
Domestic listed
UBS AG LONDON BRANCH 3,564,877 3,564,877
foreign shares
Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation
Explanation on associated
have the same actual controller, which is China National Pharmaceutical Group Corporation.
relationship among the aforesaid It is unknown that there exists no associated relationship or belongs to the consistent actionist
among the other tradable shareholders regulated by the Management Measure of Information
shareholders
Disclosure on Change of Shareholding for Listed Companies.
Explanation on shareholders Beijing Haoqing Fortune Investment Management Co., Ltd. – Haoqing Value Stable No.8
involving margin business about top
Investment Fund holds shares of the Company through margin trading and negotiable
ten common stock shareholders (if
applicable) securities account
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
6
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
√Applicable □Not applicable
1. Wages payable: a decrease of 70.9527 million Yuan compared with the beginning of the period, with a growth rate of -32.90%,
mainly because employee’s wages accrual last year are provided in the Period;
2. Asseets impairment loss: a decrease of 1.6439 million Yuan on a year-on-year basis, with a growth rate of -600.23%, mainly
because the bad debt of receivables accrual independently previous year has collected in the period, bad debt provision are switch
back;
3. Income from assets disposal: an increase of 3.7979 million Yuan on a year-on-year basis, with a growth rate of 11,709.29%,
mainly due to the account from property levied by the government in the period;
4. Other income: an increase of 331,500 Yuan on a year-on-year basis, with a growth rate of 30.46%, mainly because government
grant received in the period increased from a year earlier;
5. Non-operation revenue: a decrease of 868,300 Yuan on a year-on-year basis, with a growth rate of -38.96%, mainly because the
payable without payment has written down at same period of last year while no such changes in the period;
6. Non-operation expenditure: a decrease of 1.854 million Yuan on a year-on-year basis, with a growth rate of -74.80%, mainly due to
the arbitration penalty at same period of last year while no such changes in the period;
7. Refunds of taxes: a decrease of 98,200 Yuan on a year-on-year basis, with a growth rate of -99.61%, mainly because tax refunds
received in the period declined from a year earlier;
8. Net cash flow from operating activities: a decrease of 362 million Yuan on a year-on-year basis, with a growth rate of -72.16%,
mainly because the cash received from good sale and providing labor service declined from a year earlier;
9. Cash received from investment income: an increase of 332,500 Yuan on a year-on-year basis with a growth rate of 78.33%, mainly
because the interest for entrusted loans from affiliated enterprise in the period increased from a year earlier;
10. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: an increase of 5.556 million Yuan on
a year-on-year basis with a growth rate of 4,305.69%, mainly because the revenue from intangible assets disposal increased from a
year earlier;
11. Other cash received relating to investment activities: a decrease of 41.8152 million Yuan on a year-on-year basis, with a growth
rate of -48.73%, mainly because the margin for restructure projects are collected at same period of last year while no such account in
the period;
12. Sub-total of cash inflows from investment activities: a decrease of 35.9267 million Yuan on a year-on-year basis, with a growth
rate of -41.60%, mainly because the margin for restructure projects are collected at same period of last year while no such account in
the period;
13. Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets: an increase of 13.2185
million Yuan on a year-on-year basis, with a growth rate of 35.18%, mainly because expenditure for decoration purchasement
increased from a year earlier for more new stores open in retail section in the period;
14. Cash paid for investment: a decrease of 60 million Yuan on a year-on-year basis with a growth rate of -100%, mainly because
medical industry fund are subscribe at same period of last year while no such account in the period;
15. Net cash paid for obtaining subsidiary and other operation units: a decrease of 10 million Yuan on a year-on-year basis with a
growth rate of -100%, mainly because subscribed subsidiary’s equity at same period of last year while no such account in the period;
7
16. Other cash paid relating to investment activities: a decrease of 155 million Yuan on a year-on-year basis, with a growth rate of
-77.88%, mainly because account for equity restructuring are paid at same period of last year while no such account in the period;
17. Sub-total of cash outflows from investment activities: a decrease of 212 million Yuan on a year-on-year basis, with a growth rate
of -69.07%, mainly because account for equity restructuring are paid at same period of last year while no such account in the period;
18. Net cash flow from investment activities: an increase of 176 million Yuan on a year-on-year basis, with a growth rate of 79.86%,
mainly because account for equity restructuring are paid at same period of last year while no such account in the period;
19. Cash received by absorbing investments: an increase of 11.4932 million Yuan on a year-on-year basis, mainly because investment
from minority shareholders in the period increased from a year earlier while no such account at same period of last year;
20. Cash received from debts: a decrease of 74.8513 million Yuan on a year-on-year basis, with a growth rate of -84.56%, mainly
because the loan for current funds received from bank declined from a year earlier;
21. Other cash received relating to financing activities: an increase of 79.0805 million Yuan on a year-on-year basis, with a growth
rate of 347.71%, mainly because factoring financing in the period increased from a year earlier;
22. Cash paid for distribution of dividend, profit or interest payment: an increase of 10.2266 million Yuan on a year-on-year basis,
with a growth rate of 49.65%, mainly because the payment of buyer notes discount interest and interest of factoring financing are
increased from a year earlier;
23. Other cash paid relating to financing activities: an increase of 774,700 Yuan on a year-on-year basis, with a growth rate of
32.92%, mainly because factoring fee and financing lease interest expenditure increased from a year earlier;
24. Net cash flow from financing activities: an increase of 11.1249 million Yuan on a year-on-year basis, with a growth rate of
50.77%, mainly because factoring financing increased from a year earlier in the period
II. Analysis and explanation of significant events and their influence and solutions
√Applicable □Not applicable
The proposal on the wholly-owned subsidiary Sinopharm Group Guoda Drugstore Co.,Ltd., Bringing in Strategic
Investors by Means of Capital Increase and Share Expansion was deliberated and approved on the 25th meeting of
the 7th session of Board of Directors On Sep. 4th, 2017, and the wholly-owned subsidiary Sinopharm Group Guoda
Drugstore Co., Ltd (hereinafter referred to as “Guoda Drugstore”) has got the approval of bringing in one
strategic investor by means of capital increase and share expansion, taking assets assessment report as the
reference of pricing. The Company has been listed on stock exchanges at Shanghai United Assets and Equity
Exchange on Sep. 20th , 2017, has amassed an interested investor, as the actual controller, Walgreens Boots
Alliance (NASDAQ: WBA, hereinafter referred as “Walgreens” or “WBA”) has subscribed the stock rights of
Guoda Drugstore through taking its wholly-owned subsidiary Walgreens Boots Alliance (Hong Kong) Investments
Limited (hereinafter referred to as “WBAHKIL”) that is based in Hong Kong as the subject of capital increase,
with capital increase by 2766.70 million Yuan, it holds a 40 percent of stake of Guoda Drugstore. At beginning of
the December in 2017, the Company, Sinopharm Group Guoda Drugstore Co.,Ltd. and WBAHKIL, had signed up
the Registered Capital Increase and Subscription Agreement. On 23 March 2018, the Company received the
“Decision on Non Implementation of Further Review ” (S Anti-Monopoly CSH [2018] No.104) issued by
MOFCOM transferred from Walgreens Boots Alliance Investment Luxemburg Co., Ltd.
By the end of date of disclosure, the project needs to acquired approval of foreign investment from MOFCOM. The
Company will continue to fulfill the obligation of information disclosure according to the progress of this project.
Interim report disclosure website query
Overview of important matters Date of disclosure
index
8
Notice on Progress of the wholly-owned
subsidiary Guoda Drugstore Bringing in Juchao Website
2018-03-24
Strategic Investors by Means of Capital (http://www.cninfo.com.cn)
Increase and Share Expansion
III. Commitments completed in Period and those without completed till end of the Period
from actual controller, shareholders, related parties, purchaser and companies
□ Applicable √ Not applicable
The Company has no commitments completed in Period and those without completed till end of the Period from actual controller,
shareholders, related parties, purchaser and companies.
IV. Predict of the business performance from January to June 2018
Warnings and reasons of the predict that the cumulative net profit from the begin of the year to the end of next report period may be
loss or have great changes comparing with the same period of last year
□Applicable √Not applicable
V. Securities Investment
□ Applicable √ Not applicable
No security investment in the Period.
VI. Derivative investment
□ Applicable √ Not applicable
No derivative investment in the Period.
VII. Registration form for receiving research, communication and interview in the report
period
□Applicable √Not applicable
The Company had no receiving research, communication or interview in the report period.
VIII. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the period.
IX. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation form controlling shareholders and its related party in the period.
9
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2018-03-31
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Monetary funds 3,262,283,179.59 4,191,655,438.51
Settlement provisions
Capital lent
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Notes receivable 1,276,377,993.69 1,504,194,764.08
Accounts receivable 9,865,484,747.44 7,589,412,679.88
Accounts paid in advance 417,629,112.14 516,778,117.47
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable 57,285.56 61,441.11
Dividend receivable
Other receivables 633,837,464.61 657,871,058.54
Purchase restituted finance asset
Inventories 4,130,751,774.97 3,781,858,238.12
Assets held for sale
Non-current asset due within one
year
Other current assets 81,277,860.94 78,947,644.62
Total current assets 19,667,699,418.94 18,320,779,382.33
Non-current assets:
10
Loans and payments on behalf
Finance asset available for sales 13,685,760.00 13,685,760.00
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 1,733,234,745.09 1,650,619,373.09
Investment property 152,101,534.88 153,678,339.11
Fixed assets 554,170,016.26 551,710,434.02
Construction in progress 27,686,516.27 22,947,258.99
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 322,922,263.94 325,751,430.88
Expense on Research and
Development
Goodwill 830,729,152.75 830,729,152.75
Long-term expenses to be
251,971,852.91 252,247,050.79
apportioned
Deferred income tax asset 80,898,126.88 79,472,883.06
Other non-current asset 125,806,593.59 142,022,462.75
Total non-current asset 4,093,206,562.57 4,022,864,145.44
Total assets 23,760,905,981.51 22,343,643,527.77
Current liabilities:
Short-term loans 1,724,641,669.82 1,561,354,521.64
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 2,588,298,964.51 2,732,437,828.42
Accounts payable 7,189,784,129.58 6,144,221,000.10
Accounts received in advance 167,703,871.35 216,938,239.32
Selling financial asset of
repurchase
Commission charge and
11
commission payable
Wage payable 144,703,827.72 215,656,526.54
Taxes payable 199,482,915.87 223,752,900.24
Interest payable 6,898,654.14 7,311,819.65
Dividend payable 11,889,443.11 11,889,443.11
Other accounts payable 1,182,977,735.01 1,011,128,397.26
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Liability held for sale
Non-current liabilities due within 1
5,531,891.01 5,434,770.70
year
Other current liabilities 112,277.17 112,817.65
Total current liabilities 13,222,025,379.29 12,130,238,264.63
Non-current liabilities:
Long-term loans 31,600,000.00 31,600,000.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable 8,185,314.17 9,332,537.14
Long-term wages payable 1,777,000.00 1,777,000.00
Special accounts payable 800,000.00 800,000.00
Accrual liabilities
Deferred income 123,626,993.27 125,082,372.53
Deferred income tax liabilities 70,687,700.19 71,883,253.02
Other non-current liabilities 45,427,343.31 45,427,343.31
Total non-current liabilities 282,104,350.94 285,902,506.00
Total liabilities 13,504,129,730.23 12,416,140,770.63
Owner’s equity:
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
12
Capital public reserve 3,181,429,064.99 3,181,429,064.99
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus public reserve 214,063,491.50 214,063,491.50
Provision of general risk
Retained profit 5,865,684,491.72 5,572,952,806.39
Total owner’s equity attributable to
9,689,304,031.21 9,396,572,345.88
parent company
Minority interests 567,472,220.07 530,930,411.26
Total owner’s equity 10,256,776,251.28 9,927,502,757.14
Total liabilities and owner’s equity 23,760,905,981.51 22,343,643,527.77
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item Closing balance Opening balance
Current assets:
Monetary funds 1,164,288,622.01 1,776,696,342.87
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes receivable 9,612,441.57 64,799,618.07
Accounts receivable 704,186,741.40 480,467,760.92
Account paid in advance 629,345.64 1,138,312.26
Interest receivable 1,837,134.16 1,844,294.10
Dividends receivable
Other receivables 1,487,703,176.87 1,516,037,945.71
Inventories 189,362,652.93 172,022,676.96
Assets held for sale
Non-current assets maturing within
13
one year
Other current assets 530,332.42 788,964.90
Total current assets 3,558,150,447.00 4,013,795,915.79
Non-current assets:
Available-for-sale financial assets
Held-to-maturity investments
Long-term receivables
Long-term equity investments 7,266,721,592.63 7,180,306,084.56
Investment property 2,561,837.54 2,763,831.92
Fixed assets 17,743,826.41 13,831,103.54
Construction in progress
Project materials
Disposal of fixed assets
Productive biological assets
Oil and natural gas assets
Intangible assets 1,129,078.57 1,287,775.78
Research and development costs
Goodwill
Long-term deferred expenses 5,219,800.75 5,543,217.86
Deferred income tax assets 2,899,092.11 2,764,724.75
Other non-current assets 67,141,840.00 71,808,611.00
Total non-current assets 7,363,417,068.01 7,278,305,349.41
Total assets 10,921,567,515.01 11,292,101,265.20
Current liabilities:
Short-term borrowings 641,424,900.71 707,000,000.00
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 224,521,924.73 239,563,961.30
Accounts payable 472,847,339.30 434,886,685.35
Accounts received in advance 1,283,646.71 1,912,503.90
Wage payable 23,537,311.43 33,592,851.93
Taxes payable 42,254,243.37 42,386,907.00
Interest payable 379,939.40 669,533.78
14
Dividend payable
Other accounts payable 1,000,331,066.20 1,415,053,655.18
Liability held for sale
Non-current liabilities due within 1
year
Other current liabilities 112,277.17 112,817.65
Total current liabilities 2,406,692,649.02 2,875,178,916.09
Non-current liabilities:
Long-term loans 31,600,000.00 31,600,000.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable
Long-term wages payable
Special accounts payable 800,000.00 800,000.00
Projected liabilities
Deferred income 2,007,000.00 2,054,250.00
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities
Total non-current liabilities 38,180,319.00 38,227,569.00
Total liabilities 2,444,872,968.02 2,913,406,485.09
Owners’ equity:
Share capita 428,126,983.00 428,126,983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital public reserve 4,407,091,484.13 4,407,091,484.13
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 214,063,491.50 214,063,491.50
Retained profit 3,427,412,588.36 3,329,412,821.48
Total owner’s equity 8,476,694,546.99 8,378,694,780.11
15
Total liabilities and owner’s equity 10,921,567,515.01 11,292,101,265.20
3. Consolidated Profit Statement
In RMB
Item Current Period Last Period
I. Total operating income 10,256,566,731.51 10,222,459,812.55
Including: Operating income 10,256,566,731.51 10,222,459,812.55
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 9,962,364,535.96 9,929,024,160.13
Including: Operating cost 9,138,308,909.43 9,158,010,239.31
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 26,770,236.12 29,737,745.69
Sales expenses 606,866,589.59 548,629,093.08
Administration expenses 169,516,240.49 170,428,020.23
Financial expenses 22,272,552.43 21,945,189.25
Losses of devaluation of asset -1,369,992.10 273,872.57
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed
82,615,372.00 70,987,332.61
with “-”)
Including: Investment income on
82,615,372.00 70,987,332.61
affiliated company and joint venture
Exchange income (Loss is listed
with “-”)
16
Assets disposal income (Loss is
3,830,300.39 32,434.63
listed with “-”)
Other income 1,419,763.88 1,088,241.07
III. Operating profit (Loss is listed with
382,067,631.82 365,543,660.73
“-”)
Add: Non-operating income 1,360,096.85 2,228,376.43
Less: Non-operating expense 624,679.96 2,478,659.30
IV. Total Profit (Loss is listed with “-”) 382,803,048.71 365,293,377.86
Less: Income tax expense 69,964,333.16 70,280,239.83
V. Net profit (Net loss is listed with “-”) 312,838,715.55 295,013,138.03
(I) Continuous operation net profit
312,838,715.55 295,013,138.03
(Net loss is listed with “-”)
(II) Discontinued operation net
profit (Net loss is listed with “-”)
Net profit attributable to owner’s of
292,731,685.33 272,564,318.71
parent company
Minority shareholders’ gains and
20,107,030.22 22,448,819.32
losses
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method which
will not be reclassified subsequently to
profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
17
accounted for using equity method which
will be reclassified subsequently to profit
or loss
2. Gains or losses arising
from changes in fair value of
available-for-sale financial assets
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale financial
assets
4. The effect hedging portion
of gains or losses arising from cash flow
hedging instruments
5. Translation differences
arising on translation of foreign currency
financial statements
6. Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 312,838,715.55 295,013,138.03
Total comprehensive income
292,731,685.33 272,564,318.71
attributable to owners of parent Company
Total comprehensive income
20,107,030.22 22,448,819.32
attributable to minority shareholders
VIII. Earnings per share:
(i) Basic earnings per share 0.68 0.64
(ii) Diluted earnings per share 0.68 0.64
Enterprise combine under the same control in the Period, the combined party realized net profit of 0 Yuan before combination, and
realized -1,096.00 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
4. Profit Statement of Parent Company
In RMB
Item Current Period Last Period
18
I. Operating income 838,120,017.53 802,057,016.78
Less: Operating cost 799,779,364.60 769,324,785.10
Operating tax and extras 835,459.34 1,519,528.19
Sales expenses 12,616,898.48 12,395,531.55
Administration expenses 17,050,142.14 13,154,355.35
Financial expenses -8,050,984.45 -18,888,226.18
Losses of devaluation of asset 615,777.60 -110,682.96
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is
86,415,508.07 76,265,472.96
listed with “-”)
Including: Investment income
86,415,508.07 76,265,472.96
on affiliated company and joint venture
Assets disposal income (Loss is
1,087.38
listed with “-”)
Other income 326,108.76 641,300.00
II. Operating profit (Loss is listed with
102,014,976.65 101,569,586.07
“-”)
Add: Non-operating income 1.36 6,429.22
Less: Non-operating expense 127,688.63 1,011,760.15
III. Total Profit (Loss is listed with “-”) 101,887,289.38 100,564,255.14
Less: Income tax expense 3,887,522.50 6,181,603.71
IV. Net profit (Net loss is listed with
97,999,766.88 94,382,651.43
“-”)
(I) Continuous operation net profit
97,999,766.88 94,382,651.43
(Net loss is listed with “-”)
(II) Discontinued operation net
profit (Net loss is listed with “-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
19
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
2. Gains or losses arising
from changes in fair value of
available-for-sale financial assets
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale
financial assets
4. The effect hedging
portion of gains or losses arising from
cash flow hedging instruments
5. Translation differences
arising on translation of foreign
currency financial statements
6. Other
VI. Total comprehensive income 97,999,766.88 94,382,651.43
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Cash Flow Statement
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 9,559,665,373.83 10,328,284,481.94
services
Net increase of customer deposit
and interbank deposit
20
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
investment
Net increase of amount from
disposal financial assets that measured
by fair value and with variation
reckoned into current gains/losses
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 389.03 98,628.11
Other cash received concerning
148,125,927.35 207,536,266.55
operating activities
Subtotal of cash inflow arising from
9,707,791,690.21 10,535,919,376.60
operating activities
Cash paid for purchasing
commodities and receiving labor 9,484,567,939.67 9,820,844,639.93
service
Net increase of customer loans
and advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 506,267,191.33 479,482,361.89
Taxes paid 263,785,194.50 295,430,548.56
21
Other cash paid concerning
317,887,654.67 442,425,102.33
operating activities
Subtotal of cash outflow arising from
10,572,507,980.17 11,038,182,652.71
operating activities
Net cash flows arising from operating
-864,716,289.96 -502,263,276.11
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
757,007.78 424,502.22
income
Net cash received from disposal of
fixed, intangible and other long-term 5,685,052.04 129,038.95
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
44,000,000.00 85,815,179.38
investing activities
Subtotal of cash inflow from investing
50,442,059.82 86,368,720.55
activities
Cash paid for purchasing fixed,
50,791,078.84 37,572,554.85
intangible and other long-term assets
Cash paid for investment 60,000,000.00
Net increase of mortgaged loans
Net cash received from
10,000,000.00
subsidiaries and other units obtained
Other cash paid concerning
43,999,800.00 198,944,422.63
investing activities
Subtotal of cash outflow from investing
94,790,878.84 306,516,977.48
activities
Net cash flows arising from investing
-44,348,819.02 -220,148,256.93
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
11,493,200.00
investment
Including: Cash received from
11,493,200.00
absorbing minority shareholders’
22
investment by subsidiaries
Cash received from loans 13,671,657.79 88,522,962.94
Cash received from issuing bonds
Other cash received concerning
101,823,564.80 22,743,050.43
financing activities
Subtotal of cash inflow from financing
126,988,422.59 111,266,013.37
activities
Cash paid for settling debts 60,000,000.00 66,403,745.30
Cash paid for dividend and profit
30,822,293.85 20,595,737.67
distributing or interest paying
Including: Dividend and profit of
minority shareholder paid by 2,581,864.12 508,903.35
subsidiaries
Other cash paid concerning
3,127,895.57 2,353,233.82
financing activities
Subtotal of cash outflow from
93,950,189.42 89,352,716.79
financing activities
Net cash flows arising from financing
33,038,233.17 21,913,296.58
activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
-876,026,875.81 -700,498,236.46
equivalents
Add: Balance of cash and cash
3,673,498,691.48 3,150,915,425.49
equivalents at the period -begin
VI. Balance of cash and cash
2,797,471,815.67 2,450,417,189.03
equivalents at the period -end
6. Cash Flow Statement of Parent Company
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 762,534,474.46 742,518,400.20
services
Write-back of tax received
23
Other cash received concerning
35,545,170.43 7,196,336.45
operating activities
Subtotal of cash inflow arising from
798,079,644.89 749,714,736.65
operating activities
Cash paid for purchasing
commodities and receiving labor 809,539,295.55 802,517,675.95
service
Cash paid to/for staff and workers 28,353,128.47 25,437,740.17
Taxes paid 9,359,247.21 31,457,445.98
Other cash paid concerning
5,064,967.04 5,269,455.38
operating activities
Subtotal of cash outflow arising from
852,316,638.27 864,682,317.48
operating activities
Net cash flows arising from operating
-54,236,993.38 -114,967,580.83
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
15,164,809.14 18,996,884.57
income
Net cash received from disposal of
fixed, intangible and other long-term
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
567,200,000.00 628,959,200.00
investing activities
Subtotal of cash inflow from investing
582,364,809.14 647,956,084.57
activities
Cash paid for purchasing fixed,
3,475,188.15 2,112,339.07
intangible and other long-term assets
Cash paid for investment 60,000,000.00
Net cash received from
10,000,000.00
subsidiaries and other units
Other cash paid concerning
564,900,000.00 962,127,450.00
investing activities
Subtotal of cash outflow from investing 568,375,188.15 1,034,239,789.07
24
activities
Net cash flows arising from investing
13,989,620.99 -386,283,704.50
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from loans 10,000,000.00 10,000,000.00
Cash received from issuing bonds
Other cash received concerning
3,631,131,894.36 2,494,200,152.44
financing activities
Subtotal of cash inflow from financing
3,641,131,894.36 2,504,200,152.44
activities
Cash paid for settling debts 10,000,000.00 10,000,000.00
Cash paid for dividend and profit
9,054,055.96 1,542,929.92
distributing or interest paying
Other cash paid concerning
4,194,238,186.87 2,571,601,495.22
financing activities
Subtotal of cash outflow from
4,213,292,242.83 2,583,144,425.14
financing activities
Net cash flows arising from financing
-572,160,348.47 -78,944,272.70
activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
-612,407,720.86 -580,195,558.03
equivalents
Add: Balance of cash and cash
1,776,696,342.87 1,342,041,409.86
equivalents at the period -begin
VI. Balance of cash and cash
1,164,288,622.01 761,845,851.83
equivalents at the period -end
II. Audit report
Whether the first quarterly report had been audited or not
□ Yes √ No
The first quarterly report of the Company had not been audited.
China National Accord Medicines Corporation Ltd.
25
Legal representative: Lin Zhaoxiong
24 April 2018
26
